ActonelThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7

334 records returned

Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the JawsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: BRONJ is relatively rare but has been increasingly recognized in our clinic. The usefulness of the serum CTX value as an index of risk prediction continues to be debated. Considering the staging of lesions and the number of lesions, we found a significant correlation between the disease severity and the risk assessment using serum CTX. (Source: Journal of Oral and Maxillofacial Surgery)
Source: Journal of Oral and Maxillofacial Surgery - November 19, 2009 Category: ENT & OMF Authors: Yong-Dae Kwon, Deog-Yoon Kim, Joo-Young Ohe, Ji-Yeon Yoo, Christian Walter Tags: Basic and Patient-Oriented Research Source Type: journals

Differences between bisphosphonates in binding affinities for hydroxyapatite.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bisphosphonates (BPs) inhibit bone resorption and are widely used for the treatment of bone diseases, including osteoporosis. BPs are also being studied for their effects on hydroxyapatite (HAP)-containing biomaterials. There is a growing appreciation that there are hitherto unexpected differences among BPs in their mineral binding affinities that affect their pharmacological and biological properties. To study these differences, we have developed a method based on fast performance liquid chromatography using columns of HAP to which BPs and other phosphate-containing compounds can adsorb and be eluted by using phosphat...
Source: Biomed Res - November 10, 2009 Category: Research Authors: Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH, Russell RG Tags: J Biomed Mater Res B Appl Biomater Source Type: journals

Prescription of anti-osteoporosis drugs during 2004–2007—a nationwide register study in NorwayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion There was an increasing prevalence and a decreasing incidence of AOD use over this limited time period. There was substantial geographical variation in the prevalence of anti-osteoporosis drugs. We also observed a high minimum refill rate. Content Type Journal ArticleCategory Pharmacoepidemiology and PrescriptionDOI 10.1007/s00228-009-0746-0Authors Helene M. Devold, Norwegian Institute of Public Health Department of Chronic Diseases P.b. 4404 Nydalen 0403 Oslo NorwayGia Man Doung, Norwegian Institute of Public Health Department of Chronic Diseases P.b. 4404 Nydalen 0403 Oslo NorwayAage Tverd...
Source: European Journal of Clinical Pharmacology - November 6, 2009 Category: Drugs & Pharmacology Tags: European Journal of Clinical Pharmacology Source Type: journals

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Procter Gamble Pharmaceuticals, Inc.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Nov 2, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - November 2, 2009 Category: Drugs & Pharmacology Source Type: organizations

P&G: Actonel reduced fracturesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Procter & Gamble Co. said a program to promote its Actonel osteoporosis drug, which is in the process of being sold, has resulted in a reduced reimbursement rate for broken bones. (PG) (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 29, 2009 Category: Biotechnology Source Type: journals

P&G: Actonel reduced fracturesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Procter & Gamble Co. said a program to promote its Actonel osteoporosis drug, which is in the process of being sold, has resulted in a reduced reimbursement rate for broken bones. (PG) (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - October 29, 2009 Category: Hospital Management Source Type: journals

The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness AnalysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Based on "real world" data the analysis supports the first line use of risedronate for the treatment of osteoporotic women in Germany. (Source: Value in Health)
Source: Value in Health - October 27, 2009 Category: Global & Universal Authors: Melissa Thompson, Margaret Pasquale, Daniel Grima, Werner Moehrke, Hans Peter Kruse Source Type: journals

Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolismEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Bisphosphonates seem associated with an increased risk of DVT/PE. However, the association does not seem to be causal. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1091-yAuthors P. Vestergaard, Aarhus University Hospital Department of Endocrinology and Metabolism C Tage Hansens Gade 2 8000 Arhus C DenmarkK. Schwartz, University of Copenhagen Department of Oral and Maxillofacial Surgery, Institute of Odontology, Faculty of Health Sciences Norre alle 20 2200 Copenhagen N DenmarkE. M. Pinholt, University of Copenhagen Department of Oral and Maxillofacial Surgery, I...
Source: Osteoporosis International - October 26, 2009 Category: Orthopaedics Tags: Osteoporosis International Source Type: journals

Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Understanding of the benefits of bisphosphonate treatment can be maximised by evaluating complementary data from RCTs and observational database studies. Fracture risk reduction with bisphosphonates is shown in RCTs and in real-world clinical settings. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - October 19, 2009 Category: Internal Medicine Authors: S. Boonen, R. Kay, C. Cooper, P. Haentjens, D. Vanderschueren, F. Callewaert, K. Milisen, S. Ferrari Source Type: journals

Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic WomenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens. Content Type Journal ArticleDOI 10.1007/s00223-009-9294-yAuthors Yoon-Sok Chung, Ajou University School of Medicine Department of Endocrinology and Metabolism Suwon KoreaSung-Kil Lim, Yonsei University College of Medicine Division of Endocrinology and Metabolism, Department of Internal Medicine 134 Shinchon-dong, Seodaemun-gu Seoul 120-752 South KoreaHo-Yeo...
Source: Calcified Tissue International - October 9, 2009 Category: Orthopaedics Tags: Calcified Tissue International Source Type: journals

The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Strength/weight training exercises may prevent loss of BMD in postmenopausal BCS at risk for bone loss. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1083-yAuthors N. L. Waltman, University of Nebraska Medical Center College of Nursing Lincoln Division 1230 “O” Street, Ste. 131 Lincoln NE 685880220 USAJ. J. Twiss, University of Nebraska Medical Center College of Nursing Omaha Division Omaha NE USAC. D. Ott, University of Nebraska Medical Center College of Nursing Kearney Division Kearney NE USAG. J. Gross, University of Nebraska Medical Center College of Nurs...
Source: Osteoporosis International - October 3, 2009 Category: Orthopaedics Tags: Osteoporosis International Source Type: journals

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Certain patient characteristics are predictors of physicians prescribing oral bisphosphonates. However, many patients remain untreated. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1079-7Authors C. Asche, University of Utah School of Medicine Salt Lake UT USAR. Nelson, University of Utah School of Medicine Salt Lake UT USAC. McAdam-Marx, University of Utah School of Medicine Salt Lake UT USAM. Jhaveri, Sanofi-Aventis Bridgewater NJ USAX. Ye, University of Utah School of Medicine Salt Lake UT USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Prin...
Source: Osteoporosis International - October 1, 2009 Category: Orthopaedics Tags: Osteoporosis International Source Type: journals

Genistein-like isoflavones suppress net bone resorption in postmenopausal womenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dietary supplements containing genistein-like isoflavones suppress net bone resorption in postmenopausal women, although effects are modest compared with estrogen or risedronate therapy, show US study findings. (Source: MedWire News - Ob/Gyn)
Source: MedWire News - Ob/Gyn - September 21, 2009 Category: OBGYN Source Type: news

British doctor faces action over claims of 'ghost writing'Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
• Medics credited with work of firms' employees• US court documents reveal 'author' cultureDoctors have been agreeing to be named as authors on studies written by employees of the pharmaceutical industry, giving greater credibility to medical research, according to new evidence.The Guardian has learned that one of Britain's leading bone specialists is facing disciplinary action over accusations that he was involved in "ghost writing".The wider phenomenon has come to light through documents disclosed in the US courts which have revealed a culture in which doctors agree to "author" studies written by employees of drug fi...
Source: Guardian Unlimited Science - September 18, 2009 Category: Science Authors: Sarah Boseley Tags: Medical research Pharmaceuticals industry Procter & Gamble GlaxoSmithKline Business Science Health Society UK news United States World news Doctors The Guardian Source Type: news

Confounder summary scores when comparing the effects of multiple drug exposuresEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Little information is available comparing methods to adjust for confounding when considering multiple drug exposures. We compared three analytic strategies to control for confounding based on measured variables: conventional multivariable, exposure propensity score (EPS), and disease risk score (DRS).Each method was applied to a dataset (2000-2006) recently used to examine the comparative effectiveness of four drugs. The relative effectiveness of risedronate, nasal calcitonin, and raloxifene in preventing non-vertebral fracture, were each compared to alendronate. EPSs were derived both by using multinomial logistic regress...
Source: Pharmacoepidemiology and Drug Safety - September 14, 2009 Category: Drugs & Pharmacology Authors: Suzanne M. Cadarette, Joshua J. Gagne, Daniel H. Solomon, Jeffrey N. Katz, Til Stürmer Source Type: journals

Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The dataset obtained from the yeast screen was validated in a mammalian system, allowing the discovery of new biological processes involved in the cellular response to nitrogen-containing bisphosphonates and opening up opportunities for development of new anticancer drugs. (Source: Genome Biology)
Source: Genome Biology - September 9, 2009 Category: Genetics & Stem Cells Authors: Nicoletta BiviMilena RomanelloRichard HarrisonIan ClarkeDavid HoyleLuigi MoroFulvia OrtolaniAntonella BonettiFranco QuadrifoglioGianluca TellDaniela Delneri Source Type: journals

FDA Safety Changes: Actonel, Gardasil, MyforticEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has approved safety labeling revisions for risedronate sodium tablets, human papillomavirus quadrivalent [recombinant] vaccine, and mycophenolic acid delayed-release tablets. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2009 Category: Consumer Health News Tags: Pharmacist Source Type: news

Longitudinal change in clinical fracture incidence after initiation of bisphosphonatesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Differences in the baseline fracture incidence among the cohorts may reflect differences in the risk profile of patients prescribed each bisphosphonate. The reductions observed in fracture incidence over time within each cohort suggest that the effectiveness of each bisphosphonate in clinical practice has been consistent with their efficacies demonstrated in randomized controlled trials. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1046-3Authors A. Abelson, Cleveland Clinic Mail Code A50 9500 Euclid Avenue Cleveland OH 44195 USAJ. D. Ringe, University of Col...
Source: Osteoporosis International - August 31, 2009 Category: Orthopaedics Tags: Osteoporosis International Source Type: journals

OsteoporosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The fractures that result from osteoporosis are a major public health problem. The physician needs to be aware of the major risk factors for osteoporosis and refer appropriately for bone densitometry. These risk factors include prior fracture, a family history of fracture, slender habitus, early menopause, treatment with drugs known to affect bone (glucocorticoids) and diseases known to affect bone (rheumatoid arthritis). The diagnosis of osteoporosis can be made if the bone density T-score is −2.5 or below. This information can be used with other risk factors to estimate the 10-year risk of fractures. Patients...
Source: Medicine - August 31, 2009 Category: Internal Medicine Authors: Richard Eastell Tags: Bone disorders Source Type: journals

Ireland's Warner Chilcott buys P&G drug business for $3.1BEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Warner Chilcott said Monday it bought Procter & Gamble.'s prescription drug business, including Actonel for osteoporosis, in ... (Source: USATODAY.com Health)
Source: USATODAY.com Health - August 24, 2009 Category: Consumer Health News Source Type: news

G.P.13.11 Oral bisphosphonates as prophylaxis of steroid-induced osteoporosis in Duchenne muscular dystrophyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Corticosteroids are the gold-standard treatment for muscle weakness in Duchenne muscular dystrophy (DMD). The commonest side effects of steroid treatment are weight gain, behavioural problems and, in the long term, reduction of bone mineral density, with vertebral fractures being reported in up to 75% of DMD boys on steroids. Vertebral fractures may be very debilitating, cause severe pain, and where ambulation is critical, precipitate loss of independent walking. Over a 2 year period in our clinic we observed at least 6 cases of symptomatic vertebral fracture. In adult patients on long-term steroid regimens, prevention of ...
Source: Neuromuscular Disorders - August 7, 2009 Category: Neurology Authors: A. Sarkozy, T. Cheetham, S. Pearce, D. Rawlings, M. Eagle, G.L. Vita, M. Guglieri, V. Straub, K. Bushby Tags: 14th International Congress of the World Muscle Society Source Type: journals

Actonel (Risedronate Sodium) - updated on RxListEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Actonel (Risedronate Sodium) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 7, 2009 Category: Drugs & Pharmacology Source Type: consumer

[Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and deterioration of bone microarchitecture, leading to increased fragility and subsequent increased fracture risk. Therapeutic measures therefore aim at reducing individual fracture risk. In Austria, the following drugs, all of which have been proven to reduce fracture risk, are currently registered for the treatment of postmenopausal osteoporosis: alendronate, risedronate, etidronate, ibandronate, raloxifene, teriparatide (1-34 PTH), 1-84 PTH, strontium ranelate and salmon calcitonin. Fluorides are still available, but their role in da...
Source: Nuklearmedizin - July 31, 2009 Category: Radiology Authors: Dimai HP, Pietschmann P, Resch H, Preisinger E, Fahrleitner-Pammer A, Dobnig H, Klaushofer K, Tags: Wien Med Wochenschr Suppl Source Type: journals

Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Trial): A Multicentre, Double-Blind, Double-Dummy, Randomized Controlled Trial.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Page: 521DOI: 10.1097/01.ogx.0000356937.03800.0fAuthors: Reid, David M.; Devogelaer, Jean-Pierre; Saag, Kenneth; Roux, Christian; Lau, Chak-Sing; Reginster, Jean-Yves; Papanastasiou, Philemon; Ferreira, Alberto; Hartl, Florian; Fashola, Taiwo; Mesenbrink, Peter; Sambrook, Philip N.; for the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly (HORIZON) Trial (Source: Obstetrical & Gynecological Survey)
Source: Obstetrical & Gynecological Survey - July 25, 2009 Category: OBGYN Tags: Abstract HTML PDF (319 K) Source Type: journals

Risedronate inhibits human osteosarcoma cell invasionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Given that MMP-2 and MMP-9 are instrumental in tumor cell invasion, our results suggest the risedronate could reduce osteosarcoma cell invasion. (Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - July 21, 2009 Category: Cancer & Oncology Authors: Zeng Feng XinYang Kyung KimSung Taek Jung Source Type: journals

Antiresorptive Effects of Phytoestrogen Supplements Compared to Estradiol or Risedronate in Postmenopausal Women Using 41Ca Methodology.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Dietary supplements containing genistein-like isoflavones demonstrated a significant but modest ability to suppress net bone resorption in post-menopausal women at the doses supplied in this study over a 50-d intervention period. PMID: 19584189 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - July 6, 2009 Category: Endocrinology Authors: Weaver CM, Martin BR, Jackson GS, McCabe GP, Nolan JR, McCabe LD, Barnes S, Reinwald S, Boris ME, Peacock M Tags: J Clin Endocrinol Metab Source Type: journals

Aclasta® (zoledronic acid 5mg) approved in EU to treat steroid induced osteoporosis in men and post-menopausal womenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Personal Communication Area: News Zoledronic acid 5mg, currently licensed for the treatment of osteoporosis, has received a new licence in the EU for the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture. The new indication for glucocorticoid induced osteoporosis (GIO) is based on data from a study data published in The Lancet, which found that a single intravenous (IV) dose of zoledronate was at least as effective as daily oral risedronate in maintaining lumber spinal bone mineral density (BMD) in patien...
Source: NeLM - Bone Diseases - July 1, 2009 Category: Orthopaedics Source Type: organizations

Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Risedronate, a nitrogen-containing bisphosphonate, is widely used in the clinical field for the treatment of osteoporosis. Risedronate is known to exert its effects through binding to hydroxyapatite in bone tissue, inhibiting osteoclastic activity, and inducing apoptosis of osteoclasts. The purpose of this study was to determine the effects of risedronate on osteoclast differentiation in vitro and on an inflammatory bone loss model in vivo. Risedronate inhibited osteoclast differentiation in co-culture of bone marrow cells (BMCs) and osteoblasts, and suppressed receptor activator of nuclear factor (NF)-kappaB ligand (R...
Source: Biological and Pharmaceutical Bulletin - June 30, 2009 Category: Drugs & Pharmacology Authors: Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J Tags: Biol Pharm Bull Source Type: journals

Bisphosphonate therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bisphosphonates inhibit bone resorption and bone deposition, effectively decreasing bone turnover. The most common oral bisphosphonates are alendronate (Foxamax), risedronate (Actonel), and ibandronate (Boniva). Patients who have metastatic bone disease, especially related to multiple myeloma or carcinoma of the breast or prostate, may be taking intravenous bisphosphonates to relieve bone pain. Oral forms are used to manage osteoporosis and Paget's disease. The use of these medications is generally considered lifelong. Since 2003, reports have linked widening of the periodontal ligament, tooth loss, and osteonecrosis of th...
Source: Dental Abstracts - June 30, 2009 Category: Dentistry Tags: Implants Source Type: journals

Effectiveness of Bisphosphonates for the Reduction of Clinical Fractures – An Observational StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, women aged=65 years starting treatment with any of the three bisphosphonates were followed within two databases of healthcare utilization records inclusive of years 2000–2006. Fracture risk at the time of initiating a bisphosphonate was described by utilizing, up to a 5-year history period to obtain measures of co-morbidities, medication history and a FRAX® probability of fracture. To estimate the effectiveness of each bisphosphonate, a pre-post study design was used to assess if the clinical fracture incidence decreased with adherence to an individual bisphosphonate. ‘Pre’ was defined by the fracture...
Source: Journal of Clinical Densitometry - June 30, 2009 Category: Radiology Authors: Abby Abelson, Thierry Thomas, Deborah Gold, Jeff Lange, Johann Ringe Tags: Epidemiology Source Type: journals

Osteoporosis-Related Nonvertebral Fracture Risk Reduction vs. Hitoric Control at Two Years with Risedronate 150mg Once-A-MonthEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New osteoporosis therapies are evaluated in randomized placebo-controlled trials. When evaluating alternate dosing regimens of proven therapies, it may be difficult to include a placebo group for ethical or practical reasons. Non-inferiority of the 150mg once-a-month (OAM) dose of risedronate was established in an active controlled trial (vs. risedronate 5mg daily). This analysis was done to assess the anti-fracture efficacy of OAM risedronate using historical controls.Fracture data collected as treatment emergent adverse events in the active controlled study of 150mg of risedronate was analyzed using matched historical co...
Source: Journal of Clinical Densitometry - June 30, 2009 Category: Radiology Authors: Nelson Watts, Gary Cline, David Ramsey, Jacques Brown Tags: Prevention and Treatment of Osteoporosis Source Type: journals

Risedronate 150mg Once a Month in the Treatment of Postmenopausal Osteoporosis: 2 Year Efficacy and Safety DataEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This was a 2-year randomized, double-blind, multi-center study designed to assess the efficacy and safety of a single 150mg risedronate once-a-month oral dose compared with the 5mg daily regimen. Postmenopausal women, at least 50 years of age,=5 years since last menses and a lumbar spine T-score < −2.5 or a T-score < 2.0 with at least one prevalent vertebral fracture (T4 to L4) were enrolled in the study. Patients were randomly assigned to receive risedronate 5mg daily (n=642) or 150mg once a month (n=650) in a double-blind fashion for 2 years. Study drug was taken on an empty stomach at least 30minutes before breakfast....
Source: Journal of Clinical Densitometry - June 30, 2009 Category: Radiology Authors: Michael McClung, Jose Zanchetta, Artur Racewicz, Christian Roux, Claude-Lauren Benhamou, Zulema Man, Rachelle Eusebio, Ellen Matzkin, Steven Boonen Tags: Prevention and Treatment of Osteoporosis Source Type: journals

The Efficacy and Tolerability of a Monthly Dosing Regimen of 75mg Risedronate Dosed on 2 Consecutive Days a Month for the Treatment of Postmenopausal Women with Osteoporosis – 2 Year Study ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Daily dosing with risedronate reduces the incidence of vertebral and nonvertebral fractures in patients with postmenopausal osteoporosis. To explore less frequent dosing options, this double-blind, randomized, active-controlled, parallel-group study evaluated the efficacy and safety of 75mg oral risedronate administered on 2 consecutive days a month (2CDM) compared to 5mg oral risedronate daily in women with postmenopausal osteoporosis.Subjects were postmenopausal, 50 years or older with a lumbar spine (LS) BMD T-score of (Source: Journal of Clinical Densitometry)
Source: Journal of Clinical Densitometry - June 30, 2009 Category: Radiology Authors: Michael McClung, Claude Benhamou, Zulema Man, Witold Tlustochowicz, Jose Zanchetta, Rachelle Eusobio, Ana Balske, Ellen Matzkin, Robert Recker Tags: Prevention and Treatment of Osteoporosis Source Type: journals

Treatment with Risendronate and its Effect on Postmenopausal WomenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, Risedronate therapy in postmenopausal women increases BMD at lumbar spine and femoral neck. Patients receiving Risedronate showed an improvement of BMD vs control untreated group. (Source: Journal of Clinical Densitometry)
Source: Journal of Clinical Densitometry - June 30, 2009 Category: Radiology Authors: Galesanu Corina, Natalia Lisnic, Liliana Moisii, Mihail Galesanu, Valentin Zaharia, Adrian Aancute Tags: Prevention and Treatment of Osteoporosis Source Type: journals

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Risedronate is a cost-effective agent for the treatment of established osteoporosis (osteoporosis and a prior fragility fracture) in women from the age of 50 years and older and above 65 years in women with osteoporosis alone. The results support the treatment recommendations in recent UK guidelines for osteoporosis. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0989-8Authors F. Borgström, Karolinska Institute Medical Management Centre Stockholm SwedenO. Ström, Karolinska Institute Medical Management Centre Stockholm SwedenJ. Coelho, I3 Innovus Kla...
Source: Osteoporosis International - June 30, 2009 Category: Orthopaedics Tags: Osteoporosis International Source Type: journals

The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These results demonstrate that the combination treatment of ALF and RIS at their sub-therapeutic doses can improve the mechanical properties of the spine as well as the femur and ameliorate changes in Ca metabolism in an animal model of osteoporosis, suggesting that the combination treatment of ALF and RIS has a therapeutic advantage over each monotherapy for the treatment of osteoporosis. (Source: BMC Musculoskeletal Disorders)
Source: BMC Musculoskeletal Disorders - June 15, 2009 Category: Orthopaedics Authors: Ayako ShiraishiSayaka MiyabeTakayoshi NakanoYukichi UmakoshiMasako ItoMasahiko Mihara Source Type: journals

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract To estimate the cumulative randomized evidence for the overall incidence of bisphosphonates induced jaw osteonecrosis in adjuvant treatment of breast cancer. Systematic review and meta-analysis of randomized clinical trials. Trials were located through PubMed, ISI, Cochrane Library, and major cancer scientific meetings searches. We identified 15 studies reporting data on osteonecrosis of the jaw. A total of 10,694 randomized women were included, of whom 5,312 received bisphosphonates and 5,382 received either placebo or no treatment. Osteonecrosis of the jaw was a rare event, occurring in 13 (0.24%)...
Source: Breast Cancer Research and Treatment - June 12, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

Reply to Letter to the Editor Re “Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors” by A. Luckish et al.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We agree with Yang Ye and Shen-jiang Hu that the evaluation of the effect of risedronate treatment on circulating lipoproteins would have added an interesting dimension to the present study and would have elucidated the pathophysiology for vascular action of bisphosphonates. However, our study question focused mostly on the effect of risedronate on arterial elasticity parameters, using arterial pulse-wave contour analysis . Metabolic parameters measured during the study included routine assessment of lipid profile, which didn't include the evaluation of circulating lipoproteins. Moreover, in a recently published study whic...
Source: Bone - June 11, 2009 Category: Orthopaedics Authors: M. Shargorodsky Tags: Letters to the Editor Source Type: journals

Re “Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors” by A. Luckish et al.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
I read with great interest the work by A. Luckish et al. “Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors” . Accumulating evidences suggest for a link between osteoporosis and cardiovascular disease. A population-based longitudinal study demonstrated that progression of atherosclerotic calcification is associated with bone loss in women during the menopause . Cardiovascular disease and osteoporotic fractures are major health problems and the primary causes of morbidity and mortality in postmenopausal women . (Source: Bone)
Source: Bone - June 10, 2009 Category: Orthopaedics Authors: Yang Ye, Shen-jiang Hu Tags: Letters to the Editor Source Type: journals

Risedronate on Two Consecutive Days per Month.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Page: 355DOI: 10.2165/00002512-200926040-00006Authors: Frampton, James E. (Source: Drugs & Aging)
Source: Drugs & Aging - June 7, 2009 Category: Geriatrics Tags: Abstract HTML PDF (173 K) Source Type: journals

How Does Alendronate Compare With Risedronate for Osteoporosis Prevention?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Both agents are taken once weekly, but some differences have been found in clinical trials. Medscape Pharmacists (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - June 4, 2009 Category: Universities & Medical Training Tags: Pharmacist Source Type: info

Risedronate on Two Consecutive Days per MonthEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Drugs)
Source: Drugs - June 3, 2009 Category: Geriatrics Authors: Frampton, James E. Tags: Adis Drug Profile Source Type: journals

Prevention and treatment of osteoporosis in women: an updateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Approximately 45% of all women will suffer at least one osteoporotic fracture during their lifetime. Until recently, 25–50% of postmenopausal women were on hormone therapy often with prevention of osteoporosis as their main motivation. Following the Women’s Health Initiative, however, the use of hormone therapy has decreased by 30–40% in several countries. Fortunately, several other options for pharmacological intervention have been demonstrated to decrease the risk of fractures in randomised studies. Anti-catabolic drugs include calcium plus vitamin D, oestrogen, raloxifene, and bisphosphonates (e.g. alend...
Source: Obstetrics, Gynaecology and Reproductive Medicine - June 1, 2009 Category: OBGYN Authors: Kim Brixen, Moustapha Kassem, Bo Abrahamsen Tags: Reviews Source Type: journals

Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion RCTs can be used to examine whether bisphosphonates prevent bone loss associated with intermittent GC therapy, providing metabolically active sites such as WT are employed as the primary outcome. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0960-8Authors M. H. Kriel, University of Bristol Department of Clinical Sciences at South Bristol Bristol UKJ. H. Tobias, Avon Orthopaedic Centre, Southmead Hospital Department of Academic Rheumatology Bristol BS10 5NB UKT. J. Creed, University Hospitals Bristol NHS Foundation Trust Bristol UKM. Lockett, Frenchay Hospital De...
Source: Osteoporosis International - May 30, 2009 Category: Orthopaedics Tags: Osteoporosis International Source Type: journals

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Men receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00520-009-0655-xAuthors Ann E. Kearns, Mayo Clinic Rochester 200 First Street, SW Rochester MN 55905 USADonald W. Northfelt, Mayo Clinic Arizona Scottsdale AZ 85259-5404 USAAmylou C. Dueck, Mayo Clinic Ar...
Source: Supportive Care in Cancer - May 26, 2009 Category: Cancer & Oncology Tags: Supportive Care in Cancer Source Type: journals

Clinical Investigation of C-Terminal Cross-Linking Telopeptide Test in Prevention and Management of Bisphosphonate-Associated Osteonecrosis of the JawsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The CTX test is not predictive of the development of ONJ for an individual patient but does identify those in the “risk zone,” which is a value of less than 150 pg/mL to 200 pg/mL. If medically appropriate, the bisphosphonate can be ceased so that the CTX value increases to bring the patient out of the “risk zone.” (Source: Journal of Oral and Maxillofacial Surgery)
Source: Journal of Oral and Maxillofacial Surgery - May 19, 2009 Category: ENT & OMF Authors: Ranjit Kunchur, Allan Need, Toby Hughes, Alastair Goss Tags: Basic and Patient-Oriented Research Source Type: journals

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of this study was to compare the changes on bone mineral density, and the effects on persistence and adverse events in patients treated for postmenopausal osteoporosis with generic alendronate or with branded alendronate (Fosamax®) or branded risedronate (Actonel®) once weekly. In this retrospective patient chart analysis, we reviewed the 1-year observational treatment results for 186 women (ITT population) with postmenopausal osteoporosis. Patients from our outpatient department, who had started with once-weekly bisphosphonate therapy between 36 and at least 12 months before this chart review, were...
Source: Rheumatology International - May 9, 2009 Category: Rheumatology Tags: Rheumatology International Source Type: journals

Implant failure with bisphosphonatesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bisphosphonates inhibit bone resorption and bone deposition, with the net effect of reducing bone turnover. These agents are given intravenously (IV) during chemotherapy to manage bone pain resulting from metastatic bone disease, especially that related to multiple myeloma and breast or prostate cancer. Oral bisphosphonates are used to manage osteoporosis and Paget's disease. Once patients begin taking bisphosphonates, their use is often lifelong. The most commonly prescribed oral bisphosphonates are alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva). Reports have linked widening of the periodontal liga...
Source: Dental Abstracts - May 1, 2009 Category: Dentistry Tags: Oral Medicine Source Type: journals

Evaluating the antifracture efficacy of bisphosphonates.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article presents a comprehensive review of the key efficacy data for currently available BPs, including their nondaily regimens, to assist clinicians in assessing treatment options for NVF prevention. PMID: 19463108 [PubMed - in process] (Source: Reviews on Recent Clinical Trials)
Source: Reviews on Recent Clinical Trials - April 30, 2009 Category: Cancer & Oncology Authors: Pazianas M, Epstein S, Zaidi M Tags: Rev Recent Clin Trials Source Type: journals

Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: The present study showed differential effect of vitamin K(2) and risedronate on trabecular bone in GC-treated rats. PMID: 19430549 [PubMed - in process] (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - April 29, 2009 Category: Universities & Medical Training Authors: Iwamoto J, Matsumoto H, Tadeda T, Sato Y, Yeh JK Tags: Yonsei Med J Source Type: journals